Related by context. Frequent words. (Click for all words.) 80 Presents Positive 78 FDA Orphan Drug 77 FDA Accepts 77 Completes Enrollment 76 Patient Enrollment 75 FDA Clears 75 Drug Candidate 74 Initiates Phase 73 Announces Initiation 73 Pivotal Phase III 73 Inc Therapeutic Competitors 73 Initiate Phase 72 Phase III Clinical Trial 72 Files Shelf Registration Statement 72 Positive Opinion 72 Clinical Trial Results 72 Announces Presentation 72 Preclinical Data 72 Phase III Trial 71 Single Dose 71 Receives Regulatory 71 Generic Version 71 Receives FDA Clearance 71 Patent Covering 70 Medarex logo 70 Metastatic Melanoma 70 Pivotal Phase 70 Reports Positive 70 Completes Tender Offer 70 Achieves Milestone 70 Receives Patent 70 Vertex Pharmaceuticals Announces 69 Develop Novel 69 Q2 Loss Narrows 69 refractory chronic lymphocytic 69 Chronic Hepatitis C 69 Q3 Loss Narrows 69 Regains Compliance 69 FDA Approves 69 Q1 Loss Narrows 69 Pivotal Study 69 Updates Guidance 69 Regains Compliance With 69 Inc. Nasdaq IMGN 69 Announces Publication 69 Announces Positive 69 Announces Stockholder Approval 69 submitted Biologics License 68 Significantly Reduces 68 Extends Tender Offer 68 Completes Financing 68 Q2 Loss Widens 68 Study Demonstrates 68 Receives Positive 68 Exercises Option 68 Panzem R 68 Q3 Loss Widens 68 Transcept Pharmaceuticals 68 Exploit collaboration 68 Kuvan R 68 Attains Gold Certified Partner 68 Calls Purchased 67 orphan medicinal product 67 Provides Guidance 67 FDA Clearance 67 Receives CE 67 CHEAP ONLINE PHARMACY LOW 67 Issues Guidance 67 Announces Successful Completion 67 Explore Strategic Alternatives 67 R sorafenib tablets 67 Cyclacel Pharmaceuticals 67 Advancing Drugs 67 Shows Promise 67 NASDAQ CRXL 67 Pivotal Trial 67 Recombinant Human 67 Small Molecule 67 Bullish Engulfing Pattern 67 Q4 Loss Widens 67 Receives Approval 67 Options Trader Alert 67 Orphan Drug designation 66 Belimumab 66 Commences Trading 66 Argatroban 66 Prostate Cancer Patients 66 Stockholders Approve Merger 66 Metabasis Therapeutics 66 Q1 Loss Widens 66 II Clinical Trial 66 Announces Issuance 66 Anti Inflammatory 66 Receives Notice 66 THERAPEUTICS 66 Fibrocell Science Inc. 66 CONTAINS FORWARD LOOKING STATEMENTS 66 Reduces Risk 66 Announces Stock Repurchase 66 Well Tolerated 66 NASDAQ SHPGY